PROPANEDIOIC ACID, 2-(((2-(3-((DIMETHYLAMINO)CARBONYL)-4-(((4'-(TRIFLUOROMETHYL)(1,1'-BIPHENYL)-2-YL)CARBONYL)AMINO)PHENYL)ACETYL)OXY)METHYL)-2-PHENYL-, 1,3-DIETHYL ESTER
Type II Diabetes Mellitus
Akros Pharma Inc.Small moleculePhase 2Dormant
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 42/ 100
- Competitive Position
- 95/ 100
Competitive context
142 Active assets in the Type II Diabetes Mellitus cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Liraglutide RenJi Hospital | Phase 4 | BBB |
Semaglutide Shanghai Jiao Tong University School of Medicine | Phase 4 | BBB |
Exenatide Vivani Medical, Inc | Phase 4 | BBB |
Cotadutide AstraZeneca | Phase 2 | BBB |
Dapagliflozin Bhavya Bhavya, MD | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →